NewAmsterdam Pharma Company N.V. reported $7.1M of revenue over the trailing twelve months, −89% on the year before. 8 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $7.1M (to Q2 2026). Net income: −$260M, trailing twelve months to Q2 2026. Free cash flow: −$144M, trailing twelve months to Q2 2026. Operating margin: −56427%, trailing twelve months to Q2 2026.

NAMSNewAmsterdam Pharma Company N.V.

Healthcare

$21.58-19% 1Y

$21.58

$21.1452 weeks$41.45

NAMS as reported

NewAmsterdam Pharma Company N.V. reported $7.1M of revenue over the trailing twelve months, −89% on the year before. 8 reported series are charted on this page, each one as filed.

$7.1M

Revenue, trailing twelve months · to Q2 2026 · −89% against the twelve months before

Net income: −$260M
Net income · +57% year on year · trailing twelve months to Q2 2026
Free cash flow: −$144M
Free cash flow · +16% year on year · trailing twelve months to Q2 2026
Operating margin: −56427%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for NAMS, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$7.1M	−89%	Q2 2026
Net income	−$260M	+57%	Q2 2026
EPS	−$2.16	+33%	Q2 2026
Operating margin	−56427%	n/a	Q2 2026
Net margin	−64538%	n/a	Q2 2026
ROE	−33%	n/a	Q2 2026
ROA	−30%	n/a	Q2 2026
Free cash flow	−$144M	+16%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.